BCLC-B期肝细胞肝癌治疗效果分析  

Analysis of therapeutic effect on patients with BCLC-B hepatocellular carcinoma

作　　者：郑鹏[1] 李强[1] 

机构地区：[1]天津医科大学肿瘤医院肝胆肿瘤科,国家肿瘤临床医学研究中心,天津市“肿瘤防治”重点实验室,天津300060

出　　处：《天津医科大学学报》2016年第5期421-423,427,共4页Journal of Tianjin Medical University

摘　　要：目的:分析对比手术切除与介入治疗对巴塞罗那(BCLC)分期中B期肝细胞肝癌患者的效果。方法:回顾性分析99例BCLC-B期肝细胞肝癌患者的临床资料,并将手术切除组进一步细分为2个亚组,分析各组间无病生存期及总生存期间差异。结果:手术组与介入组之间1年、2年、3年总生存率分别为81.3%、53.9%、33.1%和59.7%、42.5%、16.8%,差异具有统计学意义(P=0.024);手术组亚组B1组与B2组的1年、2年、3年的无病生存率分别为67.5%、58.9%、43.0%和63.6%、34.6%、17.1%,差异具有统计学意义(P=0.047)。结论:选择恰当的BCLC-B期的患者能够从手术切除中获益。Objective： To analyze the impact of liver resection （LR） on patients with hepatocellular carcinoma （HCC） at the Barcelona Clinic Liver Cancer （BCLC）-B stage. Methods：Ninety-nine patients with BCLC-B HCC were included in this study. Survival and recurrence analyses were performed by log-rank tests and X2 tests. Further analyses were specifically carried out for the HCC subclassification （B1 and B2） proposed recently. Results： Ninety-nine patients were included, one, two and three-year survival rates were 81.3% ,53.9% ,33.1% and 59.7% ,42.5%, 16.8% ,respectively （P = 0.024） for surgery group and TAE group. In the surgical subgroup analysis, one, two and three-year disease free rates were 67.5%, 58.9%, 43.0% and 63.6%, 34.6%, 17.1%, respectively （P =0.047）. No significant difference was observed in the overall survival analysis. Conclusion： BCLC-B stage HCC may be still a complex group, according to the updated criteria of B-stage subclassifications and selected BCLC-B stage patients may benefit from liver resection.

关 键 词：肝细胞肝癌 巴塞罗那肝癌分期 肝切除术 介入治疗 

分 类 号：R735.7[医药卫生—肿瘤]